Larsen Fin S, Saliba Faouzi
Department of Intestinal Failure and Liver Diseases, Rigshospitalet, University Hospital Copenhagen, Copenhagen, Denmark.
AP-HP Hôpital Paul Brousse, Hepato-Biliary Center and Liver Transplant ICU, University Paris Saclay, INSERM unit N°1193, Villejuif, France.
Liver Int. 2025 Mar;45(3):e15633. doi: 10.1111/liv.15633. Epub 2023 Jun 8.
Acute liver failure (ALF) results in a multitude of complications that result in multi-organ failure. This review focuses on the pathophysiological processes and how to manage with these with artificial liver support and liver transplantation (LT). The pathophysiological sequence of events behind clinical deterioration in ALF comes down to two profound consequences of the failing liver. The first is the development of hyperammonemia, as the liver can no longer synthesize urea. The result is that the splanchnic system instead of removing ammonia becomes an ammonia-producing organ system that causes hepatic encephalopathy (HE) and cerebral oedema. The second complication is caused by the necrotic liver cells that release large molecules that originate from degrading proteins, that is damage associated molecular patterns (DAMPs) which causes inflammatory activation of intrahepatic macrophages and an overflow of DAMPs molecules into the systemic circulation resulting in a clinical picture that resembles septic shock. In this context the combined use of continuous renal replacement therapy (CRRT) and plasma exchange are rational and simple ways to remove ammonia and DAMPS molecules. This combination improve survival for ALF patients deemed not appropriate for LT, despite poor prognostic criteria, but also ensure a better stability of vital organs while awaiting LT. The combination of CRRT with albumin dialysis tends to have a similar effect. Currently, the selection criteria for LT for non-paracetamol cases appear robust while the criteria for paracetamol-intoxicated patients have become more unreliable and now consist of more dynamic prognostic systems. For patients that need LT for survival, a tremendous improvement in the post-LT results has been achieved during the last decade with a survival that now reach merely 90% which is mirroring the results seen after LT for chronic liver disease.
急性肝衰竭(ALF)会引发多种并发症,进而导致多器官功能衰竭。本综述聚焦于病理生理过程以及如何通过人工肝支持和肝移植(LT)来进行处理。ALF临床恶化背后的病理生理事件序列可归结为肝脏功能衰竭的两个严重后果。第一个是高氨血症的发生,因为肝脏无法再合成尿素。结果是,内脏系统非但不能清除氨,反而成为一个产生氨的器官系统,导致肝性脑病(HE)和脑水肿。第二个并发症是由坏死的肝细胞释放出源于蛋白质降解的大分子引起的,即损伤相关分子模式(DAMPs),它会导致肝内巨噬细胞的炎症激活,并且DAMPs分子溢出到体循环中,从而产生类似于感染性休克的临床表现。在这种情况下,联合使用连续性肾脏替代疗法(CRRT)和血浆置换是清除氨和DAMPs分子的合理且简单的方法。这种联合疗法可提高那些尽管预后标准不佳但被认为不适合进行肝移植的ALF患者的生存率,同时在等待肝移植期间确保重要器官有更好的稳定性。CRRT与白蛋白透析联合使用往往有类似效果。目前,非对乙酰氨基酚病例的肝移植选择标准似乎较为可靠,而对乙酰氨基酚中毒患者的标准变得更不可靠,现在由更具动态性的预后系统组成。对于需要肝移植以维持生命的患者,在过去十年中肝移植后的结果有了巨大改善,目前生存率仅达到90%,这与慢性肝病肝移植后的结果相当。